Author of

• 20174

  +

  P2.10 - Nursing/Palliative Care/Ethics (ID 711)

  • Event: WCLC 2017
  • Type: Poster Session with Presenters Present
  • Track: Nursing/Palliative Care/Ethics
  • Presentations: 1
  • Moderators:
  • Coordinates: 10/17/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)

  • 23458

    +

    P2.10-004 - Efficacy and Safety of Viscum Album (Helixor M) to Treat Malignant Pleural Effusion in Patients with Advanced Lung Cancer  (ID 9248)

    09:30 - 09:30  |  Presenting Author(s): Yun-Gyoo Lee
    • Abstract
    • Slides

    Background:
    Lung cancer, the most common metastatic tumor to the pleura, accounts for approximately 40% of all malignant pleural effusion (MPE). Regarding symptomatic MPE, local therapies including pleurodesis and treatment of primary malignancy are required to alleviate dyspnea and/or pleuritic pain. Helixor-M made from European mistletoe (Viscum album) has been used as adjuvant anticancer treatment by boosting immune system. We have used Helixor-M as sclerosing agent for pleurodesis to control MPE. The aim of this study is to evaluate efficacy and safety of Helixor-M to control MPE.
    
    Method:
    Between 2009 and 2015, we consecutively enrolled 52 patients with lung cancer who were treated with Helixor-M for MPE and analyzed retrospectively. For pleurodesis, we instilled 100mg of Helixor-M via pleural catheter at Day 1. After 3-hour of frequent repositioning we drained residual pleural fluid. If prior procedures were not effective, we repeated this procedure up to 5 times every second day with increasing dose by 100mg. Our primary study outcome was reappearance of pleural effusion 1-month after pleurodesis.
    
    Result:
    The median age was 63 years and 77% were male. Among 52 patients, 69% were adenocarcinoma, followed by squamous cell (13%), not otherwise specified (10%), and small cell lung cancer (8%). About 85% of MPE were cytogenetically malignant. Among 52 patients, 39 (75%) were evaluable for recurrence of MPE. The 1-month recurrence rate was 49% (19/39). Among 19 patients who experienced recurrent MPE, 6 required recurrent pleural drainage. One fourth of patients experienced significant pain after pleurodesis. Only 15% of patients experienced fever.
    
    Conclusion:
    Our results suggest that a pleurodesis with Helixor-M was effective and tolerable procedure to control MPE in advanced lung cancer patients.
    
    

    Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.